


## **Claims**

1. A sulphonamide derivative of formula (I) or a physiologically acceptable salt thereof.

5



where

$R_c$  is an optionally substituted 4-6-membered heterocyclic ring containing one or more N atoms, or

$R_c$  forms together with the phenyl ring to which it is attached a benzodioxolyl group, or

$R_c$  is  $-NR^1R^2$ , where

$R^1$  is hydrogen or alkyl,


15 R<sup>2</sup> is alkyl or an optionally substituted 4-6-membered heterocyclic ring containing one or more N atoms, or


$R^1$  and  $R^2$  taken together with the nitrogen atom to which they are attached form a heterocyclic group, which may contain one or more additional heteroatoms selected from O and N and which may be substituted, or

20 R<sup>1</sup> and R<sup>2</sup> are absent and the nitrogen atom together with the adjacent carbon atom forms a heterocyclic ring, which may contain one or more additional heteroatoms selected from N, O and S and which may be substituted.

$R_A$  is a group having the formula

25





wherein

5            n is 0 or 1, and  
           R<sup>3</sup> and R<sup>4</sup> represent each independently hydrogen, halogen, aryl,  
           alkoxy, carboxy, hydroxy, alkoxyalkyl, alkoxy carbonyl, cyano, trifluoromethyl,  
           alkanoyl, alkanoylamino, trifluoromethoxy, an optionally substituted aryl or  
           heterocyclic group.

10           2. A derivative according to claim 1 where R<sup>1</sup> and R<sup>2</sup> represent  
           methyl, R<sup>3</sup> is 2-chloro and R<sup>4</sup> is 4-chloro.

          3. A derivative according to claim 1 where R<sup>1</sup> is hydrogen, R<sup>2</sup> is  
           4,6-dimethylpyrimidin-2-yl, R<sup>3</sup> is chloro and R<sup>4</sup> is chloro.

          4. A derivative according to claim 1 where R<sup>1</sup> and R<sup>2</sup> represent  
           methyl, R<sup>3</sup> is hydrogen and R<sup>4</sup> is 3,4-dimethoxyphenyl.

          5. A derivative according to claim 1 where R<sup>1</sup> and R<sup>2</sup> represent  
           methyl, R<sup>3</sup> is hydrogen and R<sup>4</sup> is 4-fluorophenyl.

          6. A derivative according to claim 1 where R<sup>1</sup> and R<sup>2</sup> represent  
           methyl, R<sup>3</sup> is hydrogen and R<sup>4</sup> is bromo.

15           7. A derivative according to claim 1, which is 4'-fluoro-biphenyl-3-  
           sulfonic acid benzo[1,3]dioxol-5-ylamide.

          8. A derivative according to claim 1, which is 4'-fluoro-biphenyl-3-  
           sulfonic acid (2-methyl-benzoxazol-6-yl)-amide.

          9. A derivative according to claim 1, which is 2,4-dichloro-N-(1,2-  
           dimethyl-1H-indol-5-yl)-N-methyl-benzenesulfonamide.

20           10. A derivative according to claim 1, which is 4'-fluoro-biphenyl-3-  
           sulfonic acid (4-dimethylaminophenyl)-methyl-amide.

          11. A derivative according to claim 1, which is N-[4-(dimethyl-  
           amino)phenyl]-4'-fluoro-2'-methyl-1,1'-biphenyl-3-sulfonamide.

25           12. A derivative according to any of claims 1 to 11 for use as an  
           inhibitor for collagen receptor integrins.

          13. A derivative according to any of the claims 1 to 11 for use as  
           an inhibitor for  $\alpha 2\beta 1$  integrin.

14. A derivative according to any of claims 1 to 11 for use as an  $\alpha 2\beta 1$  integrin I domain inhibitor.

15. A derivative according to any of claims 1 to 11 or a physiologically acceptable salt thereof for use as a medicament.


5 16. A derivative according to claim 15 for use as a medicament for treating thrombosis and cancer spread.

17. The use of a derivative according to any of claims 1 to 11 or a physiologically acceptable salt thereof for preparing a pharmaceutical composition for treating disorders relating to thrombosis and cancer spread.

10 18. A pharmaceutical composition comprising an effective amount of a derivative according to any of claims 1 to 11 or a physiologically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier.

19. A process for preparing a benzene sulphonamide according to claim 1, comprising reacting a compound of formula (II)

15



where  $R_B$ ,  $R_C$  and  $m$  are as defined above, with a compound of formula (III)

20



where  $R_A$  is as defined above and hal is halogen.